FindTrial
Sign In

Multi-center clinical controlled study of various minimally invasive techniques for different sizes of prostate hyperplasia and establishment of stratified diagnosis and treatment strategies for prostate hyperplasia

Multi-center clinical controlled study of various minimally invasive techniques for different sizes of prostate hyperplasia and establishment of stratified diagnosis and treatment strategies for prostate hyperplasia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061300
Enrollment
Unknown
Registered
2022-06-19
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

None listed

Sponsors

Changhai Hospital of Shanghai
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Patients with benign prostatic hyperplasia lead to recurrent urinary retention (failure to urinate after at least one extubation or retention twice); 2. Repeated hematuria; 3. Recurrent urinary tract infection; 4. Bladder calculi; 5. Secondary upper urinary tract hydrocephalus; 6. Drug therapy is ineffective.

Exclusion criteria

Exclusion criteria: 1. Take aspirin, warfarin and other anticoagulant drugs have a tendency to severe bleeding; 2. Urodynamics suggests neurogenic bladder; 3. Urine flow mechanics suggests weakness of bladder detrusor muscle or other conditions of poor bladder function.

Design outcomes

Primary

MeasureTime frame
Maximum urine flow rate;—

Secondary

MeasureTime frame
IPSS (International Prostate Symptom Score);QoL (Quality of life);IIEF (International Index of Erectile Function)-5;—

Countries

China

Contacts

Public ContactGao Xiaofeng

Changhai Hospital of Shanghai

gxfdoc@sina.com+86 13601600968

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026